SCHEMBL7760184

SCHEMBL7760184

O=C(O)OCc1ccccc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
MMP1 P03956 1/20 0.54
MMP2 P08253 1/20 0.54
MMP9 P14780 1/20 0.54
MMP12 P39900 1/20 0.54
IDO1 P14902 2/20 0.53
MAPT P10636 3/20 0.51
KMT2A Q03164 3/20 0.51
RAB9A P51151 2/20 0.51
POLB P06746 1/20 0.51
PKM P14618 1/20 0.51
FFAR4 Q5NUL3 2/20 0.50
PARP10 Q53GL7 1/20 0.50
FFAR1 O14842 1/20 0.50
NPC1 O15118 1/20 0.48
GPR52 Q9Y2T5 1/20 0.42
PPARG P37231 2/20 0.42
PPARA Q07869 1/20 0.42
TAAR1 Q96RJ0 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30429390 1.00 ALDH1A1 (0.56) ALDH1A1MMP1MMP2MMP9MMP12
SCHEMBL7765576 0.86 MAPT (0.56) ALDH1A1MMP1MMP2MMP9MMP12
SCHEMBL6702870 0.84 MMP1 (0.54) ALDH1A1MMP1MMP2MMP9MMP12
SCHEMBL31554190 0.82 MAPT (0.57) ALDH1A1MMP1MMP2MMP9MMP12
SCHEMBL777869 0.82 MAPT (0.57) ALDH1A1MMP1MMP2MMP9MMP12
SCHEMBL6176778 0.82 ALDH1A1 (0.55) ALDH1A1MMP1MMP2MMP9MMP12
SCHEMBL114463 0.82 PARP10 (0.57) ALDH1A1MMP1MMP2MMP9MMP12
SCHEMBL10800307 0.82 ALDH1A1 (0.56) ALDH1A1MMP1MMP2MMP9MMP12
SCHEMBL10800311 0.82 ALDH1A1 (0.52) ALDH1A1MMP1MMP2MMP9MMP12
SCHEMBL9297537 0.81 HCAR2 (0.51) ALDH1A1MMP1MMP2MMP9MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0889901-B1 PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF LHRH ANTAGONISTS ABBOTT LAB (US) 2001-09-19 EP claimed
EP-0914334-B1 PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF LHRH ANTAGONISTS ABBOTT LAB (US) 2001-05-30 EP claimed
EP-0914334-A1 PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF LHRH ANTAGONISTS Abbott Laboratories (US) 1999-05-12 EP claimed
EP-0889901-A1 PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF LHRH ANTAGONISTS Abbott Laboratories (US) 1999-01-13 EP claimed
US-5710247-A DEPROTECTING OLIGOPEPTIDE; COUPLING ABBOTT LABORATORIES (US) 1998-01-20 US claimed
US-5710246-A COUPLING OLIGOPEPTIDES; DEPROTECTING ABBOTT LABORATORIES (US) 1998-01-20 US claimed
WO-1997034923-A1 PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF LHRH ANTAGONISTS ABBOTT LABORATORIES (US) 1997-09-25 WO claimed
WO-1997034924-A1 PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF LHRH ANTAGONISTS ABBOTT LABORATORIES (US) 1997-09-25 WO claimed
US-20250326798-A1 Synthetic Process for Production of Modified GCC Receptor Agonists IRONWOOD PHARMACEUTICALS INC (US) 2025-10-23 US disclosed
US-20250197449-A1 Synthetic Process for Production of Modified GCC Receptor Agonists IRONWOOD PHARMACEUTICALS, INC. 2025-06-19 US disclosed
EP-4436981-A1 SYNTHETIC PROCESS FOR PRODUCTION OF MODIFIED GCC RECEPTOR AGONISTS Ironwood Pharmaceuticals, Inc. (US) 2024-10-02 EP disclosed
EP-4436980-A1 SYNTHETIC PROCESS FOR PRODUCTION OF MODIFIED GCC RECEPTOR AGONISTS Ironwood Pharmaceuticals, Inc. (US) 2024-10-02 EP disclosed
CN-118591551-A Synthetic methods for producing modified GCC receptor agonists 硬木药品公司 2024-09-03 CN disclosed
WO-2023097207-A1 SYNTHETIC PROCESS FOR PRODUCTION OF MODIFIED GCC RECEPTOR AGONISTS IRONWOOD PHARMACEUTICALS, INC. (US) 2023-06-01 WO disclosed
WO-2023097210-A1 SYNTHETIC PROCESS FOR PRODUCTION OF MODIFIED GCC RECEPTOR AGONISTS IRONWOOD PHARMACEUTICALS, INC. (US) 2023-06-01 WO disclosed
US-5831001-A ADMINISTERING OLIGOPEPTIDE WITH ARGININE UNITS ALLELIX BIOPHARMACEUTICALS INC. (CA) 1998-11-03 US disclosed
US-5789531-A Peptide-based inhibitors of HIV replication ALLEX BIOPHARMACEUTICALS, INC. (CA) 1998-08-04 US disclosed
US-5646120-A OLIGO- AND POLYARGININE AND DERIVATIVES ALLELIX BIOPHARMACEUTICALS, INC. (CA) 1997-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326798-A1 Synthetic Process for Production of Modified GCC Receptor Agonists GNRHR, SCTR, GIPR ALDH1A1 4023/4885MMP1 4330/4885MMP2 4837/4885
US-20250197449-A1 Synthetic Process for Production of Modified GCC Receptor Agonists GNRHR, SCTR, GIPR ALDH1A1 4023/4885MMP1 4330/4885MMP2 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.